Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab plus best supportive care in severe COVID-19
2020-001497-30Phase 3Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19), coronavirus pneumonia, acute lung injury (ALI) and 2 more comparing Ravulizumab + best supportive care with Best supportive care alone (2 arms). Primary endpoint: Survival. Status: unknown.
02
Drugs
ravulizumab
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumoniaacute lung injury (ALI)acute respiratory distress syndrome (ARDS)pneumonia
Beyond the preview
Go deeper on 2020-001497-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001497-30.